Genmab — Marts 2019
-
Der er faktisk stille på alle aktieplatforme i dag. Lidt usædvanligt. Vejret er jo ikke specielt godt uden for.
-
Biogen fejler fase 3 - der bliver godt nok tyndet ud i pipelinen rundt omkring lige nu https://finance.yahoo.com/quote/BIIB?p=BIIB&.tsrc=fin-srch
-
Alzheimers er bare monster svært at finde noget virksomt imod - mange har brændt nallerne i den indikation https://finance.yahoo.com/news/biogen-eisai-discontinue-phase-3-110000704.html
-
Netop Solsen.
-
Jeg synes egentlig dagen er fuld af lyspunkter.... i går kom superfine recepttal og GEN steg efterfølgende pænt. DEN markedsreaktion viser at markedsdeltagerne - trods alt - godt kan forstå at vi er trygt på vej.. way henover guidance for 2019! Det faktum giver mig glimmer for øjnene i ugevis
-
God morgen.
-
GSK / BCMA drug med gode resultater. https://m.firstwordpharma.com/glaxosmithkline-targets-regulatory-filings-year-end-anti-bcma-drug-gsk2857916-multiple-myeloma
-
"
Meanwhile, among Darzalex-experienced patients, the drugmaker said the ORR and median PFS were 38.5 percent and 7.9 months, respectively. GlaxoSmithKline noted that no new safety signals were observed in the study".
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind